Immunotherapy and targeted drug for advanced collecting duct kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have collecting duct carcinoma that cannot be removed with surgery, has come back, or has spread to other parts of the body.
- You must have had at least one prior cancer treatment for metastatic disease.
- You need to be at least 18 years old and younger than 80.
- You should be in good enough health to perform daily activities (ECOG score 0 or 1).
- Your major organs (bone marrow, kidneys, liver, heart) must be working well enough, as shown by standard blood and imaging tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and enfortumab vedotin (a targeted therapy)—for people with collecting duct carcinoma or renal medullary carcinoma, two rare types of kidney cancer that have spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Hear when a new Collecting Duct Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.